


AUG 06 2007

Serial No.: 10/569,566
Case No.: 21461P
Page No.: 2Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1 (currently amended): A crystalline anhydrate form of the dihydrogenphosphate salt of (2*R*)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine of structural formula I:



characterized as being a crystalline anhydrate which is designated Form I characterized by characteristic reflections obtained from the X-ray powder diffraction pattern at spectral d-spacings of 18.42, 9.35, and 6.26 angstroms.

Claim 2 (cancelled)


Claim 3 (currently amended): The crystalline anhydrate Form I of Claim 1 further characterized by characteristic reflections obtained from the X-ray powder diffraction pattern at spectral d-spacings of 5.78, 4.71, and 3.67 angstroms.

Claim 4 (currently amended): The crystalline anhydrate Form I of Claim 3 further characterized by characteristic reflections obtained from the X-ray powder diffraction pattern at spectral d-spacings of 3.99, 2.71, and 2.66 angstroms.

Claim 5 (currently amended): The crystalline anhydrate Form I of Claim 4 further characterized by the X-ray powder diffraction pattern of FIG. 1.

Serial No.: 10/569,566
 Case No.: 21461P
 Page No.: 3

Claim 6 (currently amended): A The crystalline anhydrate F_{form I} of
Claim 1 of the dihydrogenphosphate salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-
dihydro[1,2,4]triazolo- [4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine of
structural formula I:




characterized by a solid-state fluorine-19 MAS nuclear magnetic resonance spectrum showing signals at -65.3, -105.1, and -120.4 p.p.m.

Claim 7 (currently amended): The crystalline anhydrate F_{form I} of Claim 6 further characterized by a solid-state fluorine-19 MAS nuclear magnetic resonance spectrum showing signals at -80.6, -93.5, and -133.3 p.p.m.

Claim 8 (currently amended): The crystalline anhydrate F_{form I} of Claim 7 further characterized by the solid-state fluorine-19 MAS nuclear magnetic resonance spectrum of FIG. 3.

Claim 9 (currently amended): A The crystalline anhydrate F_{form I} of
Claim 1 of the dihydrogenphosphate salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-
dihydro[1,2,4]triazolo- [4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine of
structural formula I:

Serial No.: 10/569,566
 Case No.: 21461P
 Page No.: 4



characterized by the solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum of FIG. 2.

Claim 10 (currently amended) The crystalline anhydrate ~~E~~form I of Claim 1 characterized by the thermogravimetric analysis curve of FIG. 5.

Claim 11 (cancelled)

Claims 12 – 48 (withdrawn)


Claim 49 (currently amended): A pharmaceutical composition comprising a prophylactically or therapeutically effective amount of the crystalline anhydrate form salt of Claim 1 ~~or Claim 12 or a mixture thereof~~ in association with one or more pharmaceutically acceptable carriers or excipients.

Claim 50 (currently amended): A method of treating Type 2 diabetes comprising administering to a patient in need of such treatment a therapeutically effective amount of the crystalline anhydrate form salt according to Claim 1 ~~or Claim 12 or a mixture thereof~~.

Claims 51-52 (previously cancelled)

Claim 53 (new): A crystalline anhydrate form of the dihydrogenphosphate salt of (2*R*)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-*a*]pyrazin-7(8*H*)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine of structural formula I:

Serial No.: 10/569,566
Case No.: 21461P
Page No.: 5



characterized by a Differential Scanning Calorimetry (DSC) melting endotherm with an onset temperature of 215 °C, a peak temperature of 217 °C, and an enthalpy of 221 J/g.

Claim 54 (new): A drug substance comprising a detectable amount of the crystalline anhydrate form of Claim 1.

Claim 55 (new): The drug substance of Claim 54 comprising about 5% to about 100% by weight of said crystalline anhydrate form.

Claim 56 (new): The drug substance of Claim 54 comprising about 10% to about 100% by weight of said crystalline anhydrate form.

Claim 57 (new): The drug substance of Claim 54 comprising about 25% to about 100% by weight of said crystalline anhydrate form.

Claim 58 (new): The drug substance of Claim 54 comprising about 50% to about 100% by weight of said crystalline anhydrate form.

Claim 59 (new): The drug substance of Claim 54 comprising about 75% to about 100% by weight of said crystalline anhydrate form.

Claim 60 (new): The drug substance of Claim 54 comprising substantially all by weight of said crystalline anhydrate form.